Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study

Table 3 Multi-state Cox-Markov stratified hazards model for transitions in Figure 1

Variable	HR	95%CI	P value
Transition 1→2
Age (yr)	0.997	0.989-1.005	0.493
Male (no/yes)	0.789	0.615-1.013	0.062
HCV viremia (log n)	0.983	0.940-1.029	0.470
Cirrhosis (no/yes)	0.521	0.404-0.672	< 0.001
Mixed cryoglobulinemia (no/yes)	0.755	0.520-1.098	0.141
Platelet count (n × 104/mL)	1.019	1.002-1.036	0.026
eGFR (10 mL/min/1.73 m2)	1.003	0.998-1.008	0.235
Transition 1→3
Age (yr)	0.975	0.912-1.043	0.466
Male (no/yes)	2.040	0.249-16.74	0.507
HCV viremia (log n)	0.771	0.589-1.009	0.058
Cirrhosis (no/yes)	5.704	0.620-52.51	0.124
Mixed cryoglobulinemia (no/yes)	5.633	1.022-31.05	0.047
Platelet count (n × 104/mL)	0.928	0.981-1.005	0.229
eGFR (10 mL/min/1.73 m2)	1.007	0.970-1.045	0.726
Transition 2→3
Age (yr)	1.019	0.945-1.098	0.625
Male (no/yes)	3.613	0.692-18.88	0.128
HCV viremia (log n)	0.972	0.715-1.321	0.857
Cirrhosis (no/yes)	2.720	0.479-15.44	0.259
Mixed cryoglobulinemia (no/yes)	5.982	1.217-29.41	0.028
Platelet count (n × 104/mL)	0.958	0.935-0.982	< 0.001
eGFR (10 mL/min/1.73 m2)	0.948	0.915-0.985	0.005

HCV: Hepatitis C virus; HR: Hazard ratio; CI: Confidence interval; eGFR: Estimated glomerular filtration rate.